GLP-1 Drug Quiz: Which GLP-1 Is Right For Me?

TL;DR

• GLP-1 drugs (semaglutide, tirzepatide, liraglutide) reduce appetite and blood sugar, but they are not magic—plateaus are normal and often signal your body adapting, not failure.
• Semaglutide (Ozempic, Wegovy) works on one hormone; tirzepatide (Mounjaro) activates two, often producing faster early weight loss but also more nausea.
• Plateaus on GLP-1s happen for the same reason they happen without them: your metabolism adapts. Understanding this frame changes how you respond.
• The best GLP-1 for you depends on your current health, tolerance for side effects, and whether you need rapid results or steady, sustainable loss.
• A quiz can help clarify your individual context—but only a doctor can prescribe, and only your own 90-day trial tells you what works for your body.

You've probably seen the headlines: people losing 30, 50, even 70+ pounds on GLP-1 drugs like Ozempic and Mounjaro. The before-and-afters are stunning. And then you hit month four or five, the scale stops moving, and you wonder: Did the drug stop working? Did I do something wrong? Should I switch to the other one?

The answer is almost never "the drug failed you." What's actually happening is your body is adapting—which is exactly what evolution designed it to do. And that normal, expected plateau tells you important things about whether you're on the right medication, at the right dose, for your specific situation.

This guide walks you through the three main classes of GLP-1 medications, how they differ in mechanism and side-effect profile, and how to think about which one might be a fit for your body and goals—not the Instagram version of someone else's.

What GLP-1 Drugs Actually Do (And Don't Do)

GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases when you eat. It tells your pancreas to release insulin, and it signals to your brain: "You're satisfied. Stop eating." GLP-1 drugs mimic this signal, but at much higher doses.

The three main classes in use:

Semaglutide (Ozempic, Wegovy, Rybelsus)

• Mechanism: GLP-1 receptor agonist—activates only the GLP-1 pathway.
• Typical dose escalation: Start 0.25 mg weekly, increase to 0.5 mg, then 1 mg, max 2.4 mg/week (Wegovy) or 2 mg/week (Ozempic for diabetes).
• Early weight loss: 5–15% body weight in 6 months at the higher doses; slower at lower doses.
• Why it plateaus: As your body adapts to the drug and you lose weight, your caloric needs drop. You're eating less and your metabolism has adjusted to that lower intake. The appetite suppression is still working; your deficit has just shrunk.

Tirzepatide (Mounjaro, Zepbound)

• Mechanism: GLP-1 + GIP receptor agonist—activates two hormonal pathways. GIP is a second appetite-and-metabolism regulator.
• Typical dose escalation: Start 2.5 mg weekly, increase to 5 mg, then 7.5 mg, then 10 mg (and up to 15 mg in some cases).
• Early weight loss: 10–22% body weight in 6 months; often faster than semaglutide at equivalent timepoints, according to clinical trial data.
• Why it plateaus: Same adaptation logic—but because tirzepatide hits two targets, some people report the plateau is less severe. Others find it hits harder initially, so the plateau feels more dramatic when it arrives.
• Side-effect profile: Higher nausea rate in early weeks; people report stronger appetite suppression, sometimes "too strong" in weeks 2–4.

Liraglutide (Saxenda, Victoza)

• Mechanism: GLP-1 receptor agonist, like semaglutide, but older formulation.
• Typical dose: Daily injection, max 3 mg/day.
• Early weight loss: 5–10% body weight in 6 months; slower than modern semaglutide or tirzepatide, but more forgiving for people sensitive to side effects.
• Why it plateaus: Same adaptation. Lower overall weight loss means plateaus are often less noticeable because the initial drop was gradual to begin with.

The plateau is not the drug failing. It's your body succeeding at adapting to a new, lower caloric intake. This is literally how metabolism works. And it's exactly why the question "which GLP-1 is right for me" depends on your tolerance, your baseline health, and your personal response—not just on raw efficacy numbers.

Why Plateaus Happen, and What They Tell You

You're in a caloric deficit. The drug suppresses your appetite, so you eat 500–800 fewer calories per day than you used to. You lose weight consistently. Then, around month 4–6, the scale barely budges for 2–4 weeks, and you panic.

What's actually happening:

1. Your body weight has dropped. A 200-pound person needs more calories to maintain 200 lbs than a 180-pound person needs to maintain 180 lbs. Your total daily energy expenditure (TDEE) has fallen by ~10–15% because you have less body mass to maintain.

2. Your appetite suppression is still working. The drug hasn't stopped; your brain is still getting the "I'm full" signal. But you were already eating below your old baseline—now you're eating closer to your new, lower TDEE.

3. Adaptive thermogenesis kicks in. Your body, noticing a sustained caloric deficit, downregulates metabolism slightly—it's a conservation mechanism that evolved to help us survive famines. This is normal, not a sign of a broken metabolism.

4. The deficit has narrowed. If you were eating 1,200 calories and your TDEE dropped from 2,200 to 1,900 (because you lost 30 lbs), your deficit just shrunk from 1,000 cal/day to 700 cal/day. Smaller deficit = slower weight loss.

This is why the plateau is actually diagnostic information:

• If you plateau at a dose you can tolerate, that dose + that drug may be your long-term fit. You keep taking it, accepting the plateau as normal, and maybe you see small steady losses or maintenance (which is a win).
• If you plateau and it bothers you, you have options: increase the dose (if your doctor okays it), switch medications, or adjust calories/exercise (which sounds simple but is where most people need support).
• If you have severe side effects before you plateau, that drug isn't your fit, regardless of efficacy numbers. Tolerability matters more than an extra 5% of weight loss if you're miserable.

Semaglutide vs. Tirzepatide: How to Choose

Choose Semaglutide If:

• You want gentler, more gradual weight loss. Semaglutide's side effects tend to be milder and more manageable—nausea is present but often tolerable, and it decreases over weeks.
• You're sensitive to medications. Semaglutide has been in clinical use since 2017 for diabetes; we have longer real-world safety data. Some people report fewer GI issues on lower doses.
• You value simplicity. One hormone target; straightforward dose titration; decades of diabetes data to fall back on.
• You're diabetic or pre-diabetic. Ozempic (semaglutide) has strong diabetes efficacy; Mounjaro does too, but semaglutide came first in the diabetes space.
• You prefer weekly injections. Semaglutide is weekly; tirzepatide is also weekly, but some people have stronger early reactions and want something with a gentler entry curve.

Choose Tirzepatide If:

• You want faster initial results and don't mind nausea as a trade-off. Clinical trials show ~15–20% weight loss over 6 months at higher doses—faster than semaglutide at equivalent timepoints.
• You've been on semaglutide and plateaued hard. The dual-hormone mechanism can sometimes break through a semaglutide plateau, though not always. It's a legitimate second-line try.
• You're worried about long-term appetite suppression. Some patients report that tirzepatide's stronger initial effect means you need less aggressive hunger suppression over time; the adaptation feels less dramatic. (This is anecdotal, not universal.)
• You have pre-diabetes or metabolic syndrome. Tirzepatide shows strong insulin-sensitivity improvements in trials; the GIP component adds a metabolic advantage beyond appetite suppression.
• You tolerate nausea and can push through. If week 1–3 nausea doesn't scare you, tirzepatide's speed might be worth it.

Choose Liraglutide If:

• You want the lowest barrier to entry. Older, more forgiving, fewer dramatic side effects. It's the "lite" version.
• You've failed to tolerate semaglutide or tirzepatide. If both newer agents make you too nauseated, liraglutide is often gentler.
• You're in a maintenance/sustainability mindset. Liraglutide isn't about chasing rapid weight loss; it's about steady, sustainable loss with a low side-effect burden.
• Cost is a blocker. Liraglutide is older and sometimes cheaper (though still expensive).

The Candidacy Question: When GLP-1 Makes Sense

Not everyone should be on a GLP-1, and understanding why you're considering one shapes which medication is right.

Strong candidacy signs:

• BMI > 30, or BMI > 27 with metabolic disease (pre-diabetes, PCOS, fatty liver).
• Multiple failed diets; strong appetite/satiety dysregulation (you eat past fullness, can't stick to a plan).
• Weight gain despite calorie restriction efforts.
• Family history of diabetes or metabolic disease.
• You're in a realistic headspace: "This is a tool, not a magic fix. I still have to show up. But I can't do this alone."

Weak candidacy signs:

• You're at a healthy weight and want to lose 5 lbs for vanity. (GLP-1s come with real risks; they're not cosmetic.)
• You've never tried behavior change seriously. (The drug works better when you're already trying; it removes the appetite barrier, not the need for intention.)
• You can't afford the medication or don't have medical supervision. (These need monitoring.)
• You have a personal or family history of thyroid cancer or medullary thyroid carcinoma. (GLP-1s carry a black-box warning for this.)

Weight-loss-plateau candidacy (the specific angle for this quiz):

• You've lost 15–30 lbs and plateaued on diet + exercise alone → GLP-1 could break through.
• You're on GLP-1, hit a plateau, and you're debating: "Is this drug still working? Do I switch?" → Understanding that the plateau is normal metabolic adaptation, not failure, is half the battle.
• You've been on semaglutide 6+ months, plateau is hard, and you're wondering if tirzepatide is better → Possibly, but only a trial will tell. Switching makes sense if: (a) you tolerate the first drug well but results stalled, and (b) your doctor agrees it's worth trying. A third medication? Rarely warranted without other variables.

FAQ: Real Questions People Ask

How long does it take to see results on a GLP-1?

Semaglutide: 2–4 weeks (appetite suppression), 6–8 weeks (measurable weight loss). Tirzepatide: 1–2 weeks (often faster appetite suppression), 4–6 weeks (measurable loss). Liraglutide: 2–4 weeks, slower trajectory. Your individual timeline matters more than average. Some people lose fast; others are slow and steady. Both are normal.

Can I stay on GLP-1 forever?

No clear long-term studies beyond 2–3 years, so the honest answer is: We don't know. Most doctors recommend staying on GLP-1 as long as it's working and tolerable. When you stop, you typically regain weight over 6–12 months (your appetite returns to baseline). The drug isn't a cure; it's a tool you use while you're using it. Some people use it for 1–2 years, lose weight, and transition to maintenance. Others stay on indefinitely because the weight returns without it. Talk to your doctor about your timeline.

What if I'm on semaglutide and it plateaus—should I switch to tirzepatide?

Maybe. If you tolerate semaglutide well and just hit a normal plateau, your doctor might suggest: (a) increasing the dose, (b) tightening diet/exercise (the plateau is telling you calories have equalized), or (c) waiting—sometimes the plateau is 4–6 weeks and then weight loss resumes. Switching to tirzepatide makes sense if: you're at max semaglutide dose, you tolerate it well, you're motivated, and your doctor says it's worth trying. But it's a trial, not a guarantee.

What are the most common side effects, and which drug has the fewest?

All three: nausea (most common, especially weeks 1–4), constipation, appetite suppression (not always "side effect"—sometimes the goal), rare: pancreatitis, gallbladder issues. Tirzepatide typically has more nausea early on. Semaglutide is moderate. Liraglutide is gentlest. But individual variation is huge; some people tolerate tirzepatide great and get nausea on semaglutide. Only your trial tells.

If I'm on a GLP-1 and want to add exercise, how does that work?

Do it. GLP-1 doesn't replace exercise; it removes the appetite barrier so you can exercise and eat enough protein without fighting hunger. Many people find they have MORE energy and exercise adherence on GLP-1 because they're not battling appetite all day. Start gentle; don't try to run a marathon in week 2.

Will my weight come back if I stop?

In most studies: yes, over 6–12 months, people regain ~70% of the weight they lost. Some people regain it all; some keep most of the loss. It depends on whether you've built sustainable habits while on the drug. This is why the mindset "GLP-1 as a tool, not a cure" matters. Use it to create space for behavior change; build the habits while you have that space.

The Bottom Line

The "right" GLP-1 is the one your body tolerates, your doctor agrees is safe for you, and that aligns with your actual goal—not the Instagram goal.

If you're chasing the fastest possible weight loss and tolerate nausea: Tirzepatide is often the move.

If you want something proven, gentle, and sustainable for a longer timeline: Semaglutide is the default.

If you've failed tolerance on the others or want the gentlest entry: Liraglutide is underrated.

And if you hit a plateau on any of them: That's normal. It means your body is working exactly as designed. The question isn't "which drug failed"—it's "what does this plateau tell me about my deficit, my dose, and my readiness for what comes next?"

Take our GLP-1 quiz to clarify your individual context—your health history, your side-effect tolerance, and your goals. A quiz can't prescribe, but it can help you ask smarter questions in your doctor's office. And that conversation, informed by reality about how these drugs work and why plateaus happen, is where the real decision gets made.

Disclaimer: This article is for educational purposes and should not be used as medical advice. GLP-1 medications carry real risks and benefits that vary by individual. Only a licensed doctor can assess your candidacy, prescribe a medication, and monitor your response. If you're considering a GLP-1, talk to your doctor first.

Sources cited in body: Clinical trial data on semaglutide (Wilding et al., 2021, STEP trials) and tirzepatide (Jastreboff et al., 2022, SURMOUNT trials) show tirzepatide's faster early efficacy. GLP-1 mechanism: Nauck & Meier, 2016, Nat Rev Endocrinol. Metabolic adaptation in caloric deficit: Trexler et al., 2014, Nutrients. Weight regain after GLP-1 discontinuation: Garvey et al., 2016, Obesity.

Want a personalized read on this? Find Your GLP-1 Match — a few minutes, instant results.